Holen Sie sich die Stockscreener-App
127.50
0.10%
-0.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.63
Offen:
$128.45
24-Stunden-Volumen:
12.85M
Relative Volume:
1.25
Marktkapitalisierung:
$314.90B
Einnahmen:
$65.51B
Nettoeinkommen (Verlust:
$8.93B
KGV:
35.88
EPS:
3.5532
Netto-Cashflow:
$14.12B
1W Leistung:
+3.21%
1M Leistung:
+10.45%
6M Leistung:
+17.16%
1J Leistung:
+56.40%
1-Tages-Spanne:
$127.03
$131.74
1-Wochen-Bereich:
$120.16
$131.74
52-Wochen-Spanne:
$76.66
$131.74
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-02-13 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-08 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-12-18 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-11-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-10-13 | Fortgesetzt | Citigroup | Neutral |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Merck stock steadies as Keytruda drives double digit growth - ad-hoc-news.de
ETFs Investing in Merck & Co., Inc. Stocks - TradingView
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions (NYSE:MRK) - Seeking Alpha
Merck stock trades near record territory as oncology and vaccines drive revenue growth - ad-hoc-news.de
New Cholesterol Pill, Earnings Growth Boost Merck Shares - FXEmpire
Merck stock edges higher as Keytruda drives double digit growth - ad-hoc-news.de
China’s First Homegrown 9-Valent HPV Vaccine Challenges Merck’s Retreat - Caixin Global
Merck & Co Inc (MRK) Shares Surge 3.2% -- What GF Score of 72 Tells Investors - GuruFocus
Merck stock holds gains as Keytruda drives double digit revenue growth - ad-hoc-news.de
FDA Approval Adds New Cholesterol Treatment Option in Merck Portfolio - Benzinga
Illumina, Inc., Formation Bio, Astrazeneca, Merck, and Eli Lilly and Company Expand Billion Cell Atlas Alliance with New Ai Drug Developers - marketscreener.com
Merck & Co Inc Stock (MRK) Moved Up by 3.24% on Jul 16: Drivers Behind the Movement - TradingKey
Merck's cholesterol pill gets US FDA approval - Reuters
Merck cholesterol drug, Lipfendra, approved by FDA (MRK:NYSE) - Seeking Alpha
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia - Business Wire
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider - GlobeNewswire Inc.
Merck & Co Inc Stock (MRK) Moved Up by 3.05% on Jul 15: Key Drivers Unveiled - TradingKey
Earnings preview: What to expect from Merck & Co.'s report - MSN
Earnings Preview: What To Expect From Merck & Co.'s Report - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
BMO Capital Adjusts Price Target on Merck & Co to $142 From $135, Maintains Outperform Rating - marketscreener.com
Why Merck Stock Is in the Spotlight Today - Benzinga
Merck stock holds steady after a research update - ad-hoc-news.de
Merck stock holds steady as analysts assess its pipeline - ad-hoc-news.de
Merck (MRK) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Merck & Co. Inc. stock underperforms Friday when compared to competitors - MarketWatch
Merck & Co. stock holds steady as a big pharma mainstay in the S&P 500 - ad-hoc-news.de
Merck & Co. stock holds steady as oncology and vaccines underpin long-term growth - AD HOC NEWS
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Merck & Co. Inc. updates its oncology pipeline as a major S&P 500 healthcare player - AD HOC NEWS
Merck & Co. focuses on oncology and vaccines as a major global pharma player - Ad-hoc-news.de
Former Merck and NASA Veterans Join SpaceMD as Space Pharma Momentum Builds - IPO Edge
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co. highlights oncology pipeline progress as S&P 500 healthcare heavyweight. Longer-term gro - Ad-hoc-news.de
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Merck & Co. focuses on oncology pipeline as investors watch long-term growth - Ad-hoc-news.de
Merck & Co. Inc. balances pharmaceuticals growth and pipeline investment - Ad-hoc-news.de
Merck & Co (MRK) American Society of Clinical Oncology Annual Meeting 2025 Summary - Quartr
Merck & Co. highlights its pharmaceutical portfolio as investors track long-term growth prospects - AD HOC NEWS
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Merck & Co. highlights its pharmaceuticals strength as investors track long term growth - AD HOC NEWS
Merck & Co. highlights its pharmaceutical portfolio as a major global healthcare player - AD HOC NEWS
Merck & Co. looks to long-term growth as a global pharmaceutical leader - AD HOC NEWS
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
Merck & Co. Inc. stock underperforms Monday when compared to competitors - MarketWatch
Merck & Co. focuses on oncology and vaccines as investors watch long-term growth - AD HOC NEWS
HSBC Adjusts Price Target on Merck & Co to $150 From $135 - Moomoo
Rothschild & Co Redburn Adjusts Price Target on Merck to $145 From $140 - Moomoo
Merck & Company, Inc. (MRK): Investor Outlook with a 2.62% Dividend Yield and Robust Buy Ratings - DirectorsTalk Interviews
Enterprise value to revenue forward of Merck & Co., Inc. – BX:6MK - TradingView
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):